AI Article Synopsis
- - The study aimed to compare survival rates between unresectable stage III and stage IV patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with first-line EGFR-TKI.
- - The analysis included 558 patients, revealing that stage III patients had better progression-free survival (PFS) but similar overall survival (OS) compared to stage IV patients both before and after propensity score matching (PSM).
- - Ultimately, the research concluded that while stage III patients had a higher median PFS, there was no significant difference in OS between the two stages when receiving EGFR-TKI treatment.
Article Abstract
Purpose: To compare survivals between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer (NSCLC) patients receiving first-line EGFR-TKI.
Materials And Methods: Unresectable stage III and stage IV EGFR-mutated NSCLC patients were investigated from September 2012 to May 2022. Patients received EGFR-TKI as the first-line treatment. Progression-free survival (PFS) and overall survival (OS) were assessed using the Kaplan-Meier method and propensity score matching (PSM) analyses.
Results: A total of 558 patients were included: 478 (85.66%) patients were stage IV and 80 (14.34%) patients were stage III. Before PSM, stage III patients showed a better median PFS (15 vs. 13 months; =0.026) and a similar median OS (29 vs. 30 months; =0.820) compared to stage IV patients. Stage IV was an independent prognostic factor for PFS [hazard ratio (HR)=1.47, 95% confidence interval (CI): 1.06-2.04; =0.021], but not for OS (HR=1.11, 95% CI: 0.77-1.60; =0.560). After PSM, a better median PFS (15 vs. 12 months; =0.016) and a similar median OS (29 vs. 30 months; =0.960) were found between stage III and stage IV patients.
Conclusions: OS was similar between unresectable stage III and stage IV EGFR-mutated NSCLC patients receiving EGFR-TKI as the first-line treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292882 | PMC |
| http://dx.doi.org/10.18632/aging.204781 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment.
Alzheimers Dement
December 2024
Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven, Belgium.
Introduction: The longitudinal progression of synaptic loss in Alzheimer's disease (AD) and how it is affected by tau pathology remains poorly understood.
Methods: Thirty patients with amnestic mild cognitive impairment (aMCI) and 26 healthy controls underwent cognitive evaluations and tau, synaptic vesicle protein 2A (SV2A), and amyloid positron emission tomography. Twenty-one aMCI underwent 2-year follow-up (FU) investigations.
Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].
Eur J Cancer
December 2024
Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, the Netherlands; Department of Medical Oncology, Helse Førde, Svanehaugvegen 2, Førde 6812, Norway. Electronic address:
[A portrait of a doctor with Parkinson's disease].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Siberian State Medical University, Tomsk, Russia.
In a number of causes of Parkinson's disease (PD), occupation is periodically mentioned as a possible risk factor. However, a look at the complex impact of external factors on people of certain professions and the expansion of the area of risk factors in a rapidly changing world leads to the emergence of new studies. There is an assumption that the risk of developing PD is increased in doctors due to long-term exposure to stress.
View Article and Find Full Text PDFDeoxyvasicinone hybrids in the management of Alzheimer's disease: Recent advances on manmade derivatives, pharmacological activities, and structure-activity relationship.
Arch Pharm (Weinheim)
January 2025
Department of Pharmacognosy, University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.
Alzheimer's disease (AD) is a prevalent neurological illness that affects over 80% of aged adults globally in cases of dementia. Although the exact pathophysiological causes of AD remain unclear, its pathogenesis is primarily driven by several distinct biochemical alterations: (i) the accumulation of toxic Aβ plaques, (ii) the hyperphosphorylation of tau proteins, (iii) oxidative stress resulting in cell death, and (iv) an imbalance between the two main neurotransmitters, glutamate and acetylcholine (ACh). Currently, there are very few medications available and no treatment.
View Article and Find Full Text PDFThe effect of supplementary parenteral nutrition with different energy intakes on clinical outcomes of patients after gastric cancer surgery.
BMC Surg
December 2024
General Surgery Section, Zherong County Hospital, No. 8 Shangqiao Road, Ningde, Fujian, 355300, China.
Background: To investigate the effect of postoperative supplementary parenteral nutrition (SPN) containing varying energy intake levels during the early postoperative period on the clinical outcomes of patients diagnosed with gastric cancer.
Methods: Data from 237 patients, who were diagnosed with gastric cancer between January 2016 and June 2022, were retrospectively analyzed. Patients were divided into 2 groups based on mean daily SPN energy intake: low (L-SPN; < 20 kcal/kg/day); and high (H-SPN; ≥ 20 kcal/kg/day).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!